Aliases & Classifications for Neuritis

MalaCards integrated aliases for Neuritis:

Name: Neuritis 12 54 44 15 71
Peripheral Neuritis 12 6

Classifications:



External Ids:

Disease Ontology 12 DOID:1803
MeSH 44 D009443
NCIt 50 C116381
SNOMED-CT 67 247378004
UMLS 71 C0027813

Summaries for Neuritis

MalaCards based summary : Neuritis, also known as peripheral neuritis, is related to optic neuritis and acute retrobulbar neuritis, and has symptoms including sciatica and neuralgia. An important gene associated with Neuritis is NEFL (Neurofilament Light), and among its related pathways/superpathways are Neural Crest Differentiation and Rheumatoid arthritis. The drugs Acetylcholine and Dexamethasone acetate have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and t cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Neuritis

Diseases related to Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 817)
# Related Disease Score Top Affiliating Genes
1 optic neuritis 33.6 TNF MT-ND4 MPZ MBP
2 acute retrobulbar neuritis 32.9 MT-ND4 MBP
3 optic nerve disease 32.3 TNF NEFL MT-ND4 MBP
4 guillain-barre syndrome 31.8 TNF PMP22 PMP2 MPZ MBP
5 allergic encephalomyelitis 31.8 MBP CCL5
6 demyelinating disease 31.7 TNF PMP22 MPZ MBP IFNG CCL5
7 multiple sclerosis 31.6 TNF NEFL MPZ MBP IFNG CCL5
8 acute disseminated encephalomyelitis 31.5 MPZ MBP CCL4
9 relapsing-remitting multiple sclerosis 31.4 TNF MBP IFNG CCL5
10 polyneuropathy 31.4 TNF PMP22 MPZ MBP
11 meningoencephalitis 31.2 TNF MBP CCL5
12 meningitis 31.2 TNF IFNG CCL5 CCL4
13 polyradiculoneuropathy 31.1 PMP22 MPZ MBP IFNG CCL5 CCL4
14 sarcoidosis 1 31.1 TNF IFNG CCL5 CCL4
15 chronic inflammatory demyelinating polyradiculoneuropathy 31.0 PMP22 MPZ MBP IFNG CCL5 CCL4
16 proteasome-associated autoinflammatory syndrome 1 30.8 TNF IFNG CCL5
17 q fever 30.8 TNF IFNG CCL5
18 myasthenia gravis 30.8 TNF MBP IFNG CHRNG
19 mononeuropathy 30.7 TNF PMP22 MPZ
20 immune deficiency disease 30.7 TNF MBP IFNG CCL5 CCL4
21 subacute sclerosing panencephalitis 30.6 TNF MBP IFNG
22 juvenile rheumatoid arthritis 30.5 TNF IFNG CCL5
23 viral encephalitis 30.4 TNF MBP CCL5
24 keratoconjunctivitis 30.4 TNF IFNG CCL5
25 dengue disease 30.4 TNF IFNG CCL5 CCL4
26 hypertrophic neuropathy of dejerine-sottas 30.2 PMP22 NEFL MPZ MBP
27 neuropathy, hereditary, with liability to pressure palsies 30.2 PMP22 NEFL MPZ
28 sensory peripheral neuropathy 30.2 SPTLC3 PMP22 MPZ
29 erythema multiforme 30.2 TNF IFNG CCL5
30 nerve compression syndrome 30.2 TNF PMP22 MPZ
31 foot drop 30.2 PMP22 MPZ
32 aspergillosis 30.2 TNF IFNG CCL5
33 pulmonary sarcoidosis 30.2 TNF IFNG CCL5
34 temporal arteritis 30.2 TNF IFNG CCL5
35 bacterial meningitis 30.2 TNF IFNG CCL4
36 endocarditis 30.1 TNF IFNG CCL4
37 human immunodeficiency virus infectious disease 30.1 TNF IFNG CCL5 CCL4
38 soft tissue sarcoma 30.1 TNF IFNG
39 severe acute respiratory syndrome 30.1 TNF IFNG CCL5
40 parasitic protozoa infectious disease 30.1 TNF IFNG CCL5
41 viral infectious disease 30.1 TNF IFNG CCL5 CCL4
42 pulmonary tuberculosis 30.1 TNF IFNG CCL4
43 hereditary neuropathies 30.0 PMP22 MPZ MBP LMNA
44 dermatitis, atopic 30.0 TNF IFNG CCL5 CCL4
45 charcot-marie-tooth disease, demyelinating, type 1a 30.0 PMP22 PMP2 NEFL MPZ MBP
46 sensorineural hearing loss 30.0 TNF PMP22 PEX6 IARS2 HARS1
47 arthropathy 29.9 TNF IFNG HFE
48 eales disease 29.9 TNF IFNG
49 axonal neuropathy 29.8 PMP22 NEFL LMNA
50 abdominal tuberculosis 29.6 TNF IFNG

Graphical network of the top 20 diseases related to Neuritis:



Diseases related to Neuritis

Symptoms & Phenotypes for Neuritis

UMLS symptoms related to Neuritis:


sciatica, neuralgia

GenomeRNAi Phenotypes related to Neuritis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.55 IARS2
2 Decreased viability GR00240-S-1 9.55 LMNA
3 Decreased viability GR00249-S 9.55 COX6A1 LMNA MPZ NGLY1 SPTLC3
4 Decreased viability GR00381-A-1 9.55 MPZ
5 Decreased viability GR00381-A-3 9.55 MPZ
6 Decreased viability GR00386-A-1 9.55 IARS2 LMNA MPZ NEFL
7 Decreased viability GR00402-S-2 9.55 IARS2 MBP MPZ TNF

MGI Mouse Phenotypes related to Neuritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.73 CHRNG COX6A1 DNAJB5 HFE IFNG LMNA
2 nervous system MP:0003631 9.36 CHRNG COX6A1 HFE IFNG LMNA MBP

Drugs & Therapeutics for Neuritis

Drugs for Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Glatiramer Acetate Phase 4 147245-92-9 3081884
6 (T,G)-A-L Phase 4
7 Neurotransmitter Agents Phase 4
8 Botulinum Toxins Phase 4
9 Cholinergic Agents Phase 4
10 Adrenocorticotropic Hormone Phase 4
11 Antineoplastic Agents, Hormonal Phase 4
12
Simvastatin Approved Phase 3 79902-63-9 54454
13
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
14
Interferon beta-1b Approved Phase 2, Phase 3 145155-23-3
15 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
16 Hypolipidemic Agents Phase 3
17 Lipid Regulating Agents Phase 3
18 Anticholesteremic Agents Phase 3
19 Antibodies Phase 3
20 Immunoglobulins Phase 3
21 Hematinics Phase 3
22 Epoetin alfa Phase 3 113427-24-0
23 gamma-Globulins Phase 3
24 Immunoglobulins, Intravenous Phase 3
25 Rho(D) Immune Globulin Phase 3
26 Ginkgo Phase 3
27 Pharmaceutical Solutions Phase 3
28 Analgesics, Non-Narcotic Phase 2, Phase 3
29 Cyclooxygenase Inhibitors Phase 2, Phase 3
30 Anti-Inflammatory Agents, Non-Steroidal Phase 2, Phase 3
31 Analgesics Phase 2, Phase 3
32 Fingolimod Hydrochloride Phase 2, Phase 3
33
Hydrochlorothiazide Approved, Vet_approved Phase 2 58-93-5 3639
34
Amiloride Approved Phase 2 2016-88-8, 2609-46-3 16231
35
Phenytoin Approved, Vet_approved Phase 2 57-41-0 1775
36
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
37
Clemastine Approved, Investigational Phase 2 15686-51-8 26987
38
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
39
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
40
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
41
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 6221 5280795
42 Sodium Chloride Symporter Inhibitors Phase 2
43 Amiloride, hydrochlorothiazide drug combination Phase 2
44 Antihypertensive Agents Phase 2
45 Antibodies, Monoclonal Phase 2
46 Sodium Channel Blockers Phase 2
47 diuretics Phase 2
48 Diuretics, Potassium Sparing Phase 2
49 Anticonvulsants Phase 2
50 Calcium, Dietary Phase 2

Interventional clinical trials:

(show top 50) (show all 99)
# Name Status NCT ID Phase Drugs
1 A Multicenter Longitudinal Cross-sectional Pilot Study, to Compare RNFL Thickness Measured by OCT After Treatment With Glatiramer or After no Treatment in Patients With CIS With or Without Optic Neuritis or With Early RRMS Unknown status NCT00910598 Phase 4 glatiramer acetate
2 Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10) Completed NCT00179478 Phase 4 interferon beta 1a 30 ug IM once weekly
3 Probe Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4 Botulinum toxin serotype A
4 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Recruiting NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV methylprednisolone (steroids)
5 Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation Recruiting NCT03247413 Phase 4 Dexamethasone 4 mg/ml;Normal saline
6 An Open Label Pilot Study of Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event: Comparison With CHAMPS Results. Withdrawn NCT00037115 Phase 4 interferon beta 1a;methotrexate;methylprednisolone
7 Simvastatin Treatment of Patients With Acut Optic Neuritis. A Doubleblind, Randomized and Placebo Controlled Fase III Trial Unknown status NCT00261326 Phase 3 simvastatin;placebo
8 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
9 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study Unknown status NCT02220244 Phase 3 MD1003 100mg capsule
10 Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis Completed NCT01337986 Phase 2, Phase 3 Dalfampridine/Placebo;Placebo/Dalfampridine
11 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Completed NCT01962571 Phase 3 Erythropoietin alfa;Placebo
12 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3 Immunoglobulin
13 Recovery of Demyelinating Optic Neuritis After Treatment With Equivalent High Doses of Oral vs. Intravenous Corticosteroids: a Randomized Single Blinded Clinical Trial Completed NCT01524250 Phase 2, Phase 3 corticosteroids;corticosteroids
14 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON) Completed NCT00856635 Phase 3 Glatiramer Acetate;placebo
15 The Efficacy of Steroid Therapy in Vestibular Neuritis Confirmed by Head Impulse Test: Prospective Randomized Controlled Study Completed NCT02098330 Phase 3 Ginkgo biloba & Methylprednisolone;Ginkgo biloba
16 NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Multifocal Motor Neuropathy. Completed NCT01827072 Phase 3 NPB-01
17 A Randomized, Double-Blind, Placebo Controlled, Cross-over Study of the Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Multifocal Motor Neuropathy Completed NCT00666263 Phase 3
18 Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain Completed NCT02593721 Phase 2, Phase 3 Ibuprofen
19 Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis Terminated NCT01647880 Phase 2, Phase 3 Verum arm receiving Gilenya®;Active Comparator receiving Extavia®
20 The Investigation Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2 Vitamin D;Vitamin D withheld
21 A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis Unknown status NCT01879527 Phase 2 Amiloride hydrochlorothiazide;Sugar pill
22 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis Completed NCT01721161 Phase 2 Placebo
23 A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis Completed NCT01802489 Phase 2 Amiloride;Placebo
24 A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201 Completed NCT02657915 Phase 2 Placebo;BIIB033 100mg/Kg
25 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2
26 Double Blind, Placebo-controlled Study to Determine the Safety and Efficacy of Erythropoietin as an add-on Therapy of Methylprednisolone in Subjects With Acute Optic Neuritis (VISION PROTECT) Completed NCT00355095 Phase 2 Erythropoietin
27 A Phase II Double Blind, Randomized, Placebo Controlled Trial of Neuroprotection With Phenytoin in Acute Optic Neuritis Completed NCT01451593 Phase 2 Phenytoin;Placebo
28 a Phase II Double Blind, Randomized, Placebo Controlled Trial of Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer (GCIPL) Thickness and Visual Field in Patients With a First Episode of Acute Optic Neuritis Completed NCT02939937 Phase 2 Phenytoin;placebo
29 A Controlled Cross-Over Trial of Subcutaneous Versus Intravenous Immunoglobulin for Multifocal Motor Neuropathy Completed NCT00268788 Phase 2 Subcutaneous immunoglobulin;Intravenous immunoglobulin
30 A Multicentre Study of Subcutaneous Immunoglobulin (SCIG) in Patients With Multifocal Motor Neuropathy (MMN) Completed NCT00701662 Phase 2
31 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
32 Randomized, Single-blind, Cross-over Study Investigating the Non-inferiority of Efficacy and Safety of HyQvia in Comparison With Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy Completed NCT02556437 Phase 2 HyQvia;Subcuvia
33 A Double-blind, Placebo-controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients With Multiple Sclerosis Completed NCT00772525 Phase 2 Nerispirdine;Placebo
34 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
35 A Phase II Trial of High-Dose Vitamin D Induction in Optic Neuritis (VitaDON 2) Recruiting NCT03302585 Phase 2 Vitamin D3;Placebo/Standard of Care Vitamin D3
36 A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis Recruiting NCT02521311 Phase 2 Clemastine;Placebo
37 Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial Active, not recruiting NCT02976766 Phase 2 Gypenosides;Placebo
38 A Two-arm, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Safety and Tolerability and to Explore the Neuroprotective Effect of Atacicept as Assessed by Optical Coherence Tomography (OCT) in Subjects With Optic Neuritis (ON) as Clinically Isolated Syndrome (CIS) Over a 36-week Treatment Course Terminated NCT00624468 Phase 2 Atacicept;Placebo matched to atacicept
39 Developing Neuroprotection and Repair Strategies in MS: Phase IIa Randomized, Controlled Trial of Minocycline in Acute Optic Neuritis (ON) Terminated NCT01073813 Phase 2 Minocycline
40 A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis Terminated NCT01757691 Phase 2 Fingolimod 0.5mg/daily;Placebo
41 Lipoic Acid as a Treatment for Acute Optic Neuritis: A Pilot Study Completed NCT01294176 Phase 1 Lipoic Acid
42 A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers Completed NCT02833142 Phase 1 BIIB033 (opicinumab)
43 A Randomised, Double-blind, Placebo-controlled, Single (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BN201 in Healthy Subjects Completed NCT03630497 Phase 1 Comparison of BN201 treatment with Placebo
44 An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD). Completed NCT01777412 Phase 1 Bevacizumab
45 Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) Completed NCT02276963 Phase 1 Ublituximab
46 Open Label Study of Safety and Tolerability of Rituximab in Neuromyelitis Optica, Recurrent Transverse Myelitis and Recurrent Bilateral Simultaneous Optic Neuritis Completed NCT00501748 Phase 1 Rituximab
47 The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging Unknown status NCT03451955
48 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
49 Longitudinal Optic Neuritis Study (LONS) Unknown status NCT00000147 Methylprednisolone;Prednisone
50 Linking Optic Nerve Lesion Length at MRI and the Retinal Axonal Loss at 12 Months From a Clinical Episode of Optic Neuritis Unknown status NCT03651362

Search NIH Clinical Center for Neuritis

Cochrane evidence based reviews: neuritis

Genetic Tests for Neuritis

Anatomical Context for Neuritis

MalaCards organs/tissues related to Neuritis:

40
Brain, Eye, T Cells, Spinal Cord, Retina, Breast, Pituitary

Publications for Neuritis

Articles related to Neuritis:

(show top 50) (show all 10568)
# Title Authors PMID Year
1
Alpha- and gamma-synuclein proteins are present in cerebrospinal fluid and are increased in aged subjects with neurodegenerative and vascular changes. 54 61
18577885 2008
2
Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease. 54 61
16753180 2006
3
Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. 54 61
16519780 2006
4
Guillain-Barré syndrome. 61 54
16271648 2005
5
Sequential expression of chemokines in experimental autoimmune neuritis. 61 54
11024541 2000
6
Pathogenesis of Guillain-Barré syndrome. 61 54
10695718 1999
7
Induction of experimental autoimmune neuritis with peripheral myelin protein-22. 54 61
9798745 1998
8
Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. 61 54
9776709 1998
9
Effect of lipids on the conformation of an antigenic determinant for experimental autoimmune neuritis. 54 61
9584990 1998
10
Antigen therapy eliminates T cell inflammation by apoptosis: effective treatment of experimental autoimmune neuritis with recombinant myelin protein P2. 61 54
9037054 1997
11
The antibody repertoire in experimental allergic neuritis: evidence for PMP-22 as a novel neuritogen. 61 54
8982118 1996
12
Conformation of an antigenic determinant for experimental autoimmune neuritis. 61 54
8694832 1996
13
Human peripheral myelin protein-22 carries the L2/HNK-1 carbohydrate adhesion epitope. 61 54
7693873 1993
14
Pathogenesis of immune-mediated neuropathies. 61 54
8381954 1993
15
Shared T-cell receptor gene usage in experimental allergic neuritis and encephalomyelitis. 61 54
1381167 1992
16
[Immunoregulation disturbance in experimental allergic neuritis. The cellular and humoral mediated immunological damage]. 61 54
1711438 1990
17
Macrophages but not Schwann cells express Ia antigen in experimental autoimmune neuritis. 61 54
2375636 1990
18
Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. 61
33604462 2021
19
Utilization of Visual Acuity Retroilluminated Charts for the Assessment of Afferent Visual System Dysfunction in a Pediatric Neuroimmunology Population. 61
32868561 2021
20
Neurologic Causes of Thoracic Limb Lameness. 61
33558012 2021
21
Myelin oligodendrocyte glycoprotein-IgG-positive, steroid-responsive combined central and peripheral demyelination with recurrent peripheral neuropathy. 61
33078247 2021
22
Nerve conductions studies in experimental models of autoimmune neuritis: A meta-analysis and guideline. 61
33508768 2021
23
Expanding the phenotype of MOG antibody-associated disease (MOGAD): half a century of epilepsy and relapsing optic neuritis. 61
33148814 2021
24
Predictors of Visual Acuity and Usefulness of a Treatment Algorithm in Rhinogenous Optic Neuritis. 61
31550936 2021
25
Optic neuritis associated with sunitinib. 61
32914245 2021
26
Myelin Oligodendrocyte Glycoprotein Antibody-Positive Optic Neuritis Presenting as Idiopathic Orbital Inflammatory Syndrome. 61
32108670 2021
27
Sjögren Disease and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis. 61
32235221 2021
28
Comparison of macular structural and vascular changes in neuromyelitis optica spectrum disorder and primary open angle glaucoma: a cross-sectional study. 61
32430343 2021
29
Peripheral Vestibular Disorders: Nationwide Evidence From Taiwan. 61
32621538 2021
30
Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project. 61
33462778 2021
31
Predictive value of optical coherence tomography, multifocal visual evoked potentials, and full-field visual evoked potentials of the fellow, non-symptomatic eye for subsequent multiple sclerosis development in patients with acute optic neuritis. 61
32507033 2021
32
Shortened Pattern Electroretinogram Latency and Impaired Autoregulatory Dynamics to Steady-State Stimuli in Patients With Multiple Sclerosis. 61
31977664 2021
33
Raw and wine processed Schisandra chinensis attenuate anxiety like behavior via modulating gut microbiota and lipid metabolism pathway. 61
33007392 2021
34
Vestibular Neuritis as Clinical Presentation of COVID-19. 61
33570425 2021
35
Jaundice and Thrombocytopenia in an acute abdomen with concurrent Appendicitis and spontaneous Rectal perforation: An unusual presentation of human leptospirosis. 61
33530876 2021
36
A widespread rash with optic neuritis. 61
33554354 2021
37
Cavernous Sinus Thrombosis related to Orbital Cellulitis Serious Complication to Prevent: a case report and literature review. 61
33532066 2021
38
The long-term outcome of MOGAD: An observational national cohort study of 61 patients. 61
33528851 2021
39
Distal posterolateral corner injury in the setting of multiligament knee injury increases risk of common peroneal palsy. 61
33558949 2021
40
Neuroglobin alleviates arsenic-induced neuronal damage. 61
33545379 2021
41
Ilioinguinal/Iliohypogastric Pulsed Radiofrequency for the Treatment of Pediatric Chronic Abdominal Pain: A Case Report. 61
33560645 2021
42
Outcomes and Incidence of Complications Following Endoscopic Gastrocnemius Recession: A Systematic Review. 61
31928084 2021
43
Intertwined Carbon Nanotubes and Ag Nanowires Constructed by Simple Solution Blending as Sensitive and Stable Chloramphenicol Sensors. 61
33572293 2021
44
Opto-chiasmatic apoplexy as a compartment syndrome? Anatomical and surgical considerations on two bleeding cavernous malformations. 61
33418335 2021
45
Neuropsychological Phenotypes of Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Associated Disorders: A Case Series. 61
33578444 2021
46
Optic Nerve Root Enhancement in Gadolinium-Enhanced Magnetic Resonance Imaging of Rathke's Cleft Cyst. 61
33181383 2021
47
[Lesions of the anterior interosseous nerve: differentiating between compression neuropathy and neuritis]. 61
33588494 2021
48
Spontaneous Jamming of Horizontal Semicircular Canal Combined with Canalolithiasis of Contralateral Posterior Semicircular Canal. 61
33562956 2021
49
Systematic Review and Meta-analysis: Effectiveness of Corticosteroids in Treating Adults With Acute Vestibular Neuritis. 61
33525978 2021
50
Comment on: Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. 61
33608641 2021

Variations for Neuritis

ClinVar genetic disease variations for Neuritis:

6 (show top 50) (show all 92)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 IARS2 NM_018060.4(IARS2):c.2726C>T (p.Pro909Leu) SNV Pathogenic 156553 rs587783070 1:220316451-220316451 1:220143109-220143109
2 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr) SNV Pathogenic 804285 rs1131040 5:140057507-140057507 5:140677922-140677922
3 HARS1 NM_002109.6(HARS1):c.730delG Deletion Pathogenic 804286 rs1581505917 5:140057005-140057005 5:140677420-140677420
4 PEX6 NM_000287.4(PEX6):c.2356C>T (p.Arg786Trp) SNV Pathogenic 553552 rs267608239 6:42933788-42933788 6:42966050-42966050
5 PEX6 NM_000287.4(PEX6):c.371T>C (p.Leu124Pro) SNV Pathogenic 869197 6:42946518-42946518 6:42978780-42978780
6 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Pathogenic 14029 rs28928910 8:24813966-24813966 8:24956452-24956452
7 HFE NM_000410.3(HFE):c.845G>A (p.Cys282Tyr) SNV Pathogenic 9 rs1800562 6:26093141-26093141 6:26092913-26092913
8 LMNA NM_170707.4(LMNA):c.344A>T (p.Glu115Val) SNV Likely pathogenic 200932 rs794728588 1:156085053-156085053 1:156115262-156115262
9 NEFL NM_006158.5(NEFL):c.64C>T (p.Pro22Ser) SNV Likely pathogenic 14029 rs28928910 8:24813966-24813966 8:24956452-24956452
10 NGLY1 NM_018297.4(NGLY1):c.1533_1536del (p.Asn511fs) Deletion Likely pathogenic 548658 rs765211108 3:25770699-25770702 3:25729208-25729211
11 COX6A1 NM_004373.4(COX6A1):c.103+1G>C SNV Likely pathogenic 560368 rs377504835 12:120876033-120876033 12:120438230-120438230
12 CHRNG NM_005199.5(CHRNG):c.256C>T (p.Arg86Cys) SNV Likely pathogenic 397615 rs777219451 2:233405327-233405327 2:232540617-232540617
13 DNAJB5 NM_001135005.3(DNAJB5):c.43C>T (p.Pro15Ser) SNV Likely pathogenic 243086 rs774909609 9:34990670-34990670 9:34990673-34990673
14 PMP2 NM_002677.5(PMP2):c.128T>A (p.Ile43Asn) SNV Likely pathogenic 243087 rs879253869 8:82357170-82357170 8:81444935-81444935
15 SPTLC3 NM_018327.4(SPTLC3):c.448T>C (p.Trp150Arg) SNV Likely pathogenic 243088 rs755919784 20:13053048-13053048 20:13072400-13072400
16 MT-ND4 NC_012920.1:m.11896C>G SNV Uncertain significance 370054 rs1057516065 MT:11896-11896 MT:11896-11896
17 ABCA4 NM_000350.3(ABCA4):c.203C>T (p.Pro68Leu) SNV Uncertain significance 99113 rs62654397 1:94577093-94577093 1:94111537-94111537
18 MYH14 NM_001145809.2(MYH14):c.1945+6G>A SNV Uncertain significance 374064 rs1057518869 19:50756016-50756016 19:50252759-50252759
19 PNPLA6 NM_001166114.2(PNPLA6):c.1205C>T (p.Ser402Leu) SNV Uncertain significance 397619 rs372193709 19:7606906-7606906 19:7542020-7542020
20 SPTAN1 NM_001130438.3(SPTAN1):c.4039G>A (p.Asp1347Asn) SNV Uncertain significance 207286 rs574740801 9:131367749-131367749 9:128605470-128605470
21 DYSF NM_001130987.2(DYSF):c.1449G>A (p.Met483Ile) SNV Uncertain significance 288879 rs146064054 2:71762219-71762219 2:71535089-71535089
22 NEB NM_001271208.2(NEB):c.21902C>T (p.Pro7301Leu) SNV Uncertain significance 387835 rs367626762 2:152384038-152384038 2:151527524-151527524
23 MKS1 NM_001165927.1(MKS1):c.1577G>A (p.Arg526Gln) SNV Uncertain significance 397617 rs746283445 17:56283513-56283513 17:58206152-58206152
24 PRX NM_020956.2(PRX):c.*2540G>A SNV Uncertain significance 397620 rs369505684 19:40901924-40901924 19:40396017-40396017
25 KIFBP NM_015634.4(KIFBP):c.167_187dup (p.Asp56_Glu62dup) Duplication Uncertain significance 397616 rs767103634 10:70748746-70748747 10:68988990-68988991
26 SBF2-AS1 NM_030962.3(SBF2):c.5014_5016del (p.Lys1672del) Deletion Uncertain significance 397621 rs750958357 11:9809202-9809204 11:9787655-9787657
27 PHKA1 NM_002637.4(PHKA1):c.1272T>A (p.Asp424Glu) SNV Uncertain significance 397618 rs1060499719 X:71870292-71870292 X:72650442-72650442
28 NEB NM_001271208.2(NEB):c.16637G>A (p.Arg5546His) SNV Uncertain significance 257765 rs201111610 2:152435919-152435919 2:151579405-151579405
29 DNM2 NM_001005360.2(DNM2):c.190G>A (p.Val64Ile) SNV Uncertain significance 133978 rs144250390 19:10870442-10870442 19:10759766-10759766
30 KIF24 Deletion Uncertain significance 243059 9:34280042-34296294 9:34280044-34296296
31 FLRT1 NM_014067.4(MACROD1):c.517+33243C>G SNV Uncertain significance 461796 rs140274429 11:63885468-63885468 11:64117996-64117996
32 FLRT1 NM_014067.4(MACROD1):c.517+34934G>C SNV Uncertain significance 461801 rs139768227 11:63883777-63883777 11:64116305-64116305
33 FLRT1 NM_014067.4(MACROD1):c.517+33881C>T SNV Uncertain significance 565723 rs767022154 11:63884830-63884830 11:64117358-64117358
34 FLRT1 NM_014067.4(MACROD1):c.517+34196G>A SNV Uncertain significance 566239 rs776773158 11:63884515-63884515 11:64117043-64117043
35 FLRT1 NM_014067.4(MACROD1):c.517+33604C>A SNV Uncertain significance 566560 rs1395376914 11:63885107-63885107 11:64117635-64117635
36 FLRT1 NM_014067.4(MACROD1):c.517+33719C>T SNV Uncertain significance 568577 rs769032516 11:63884992-63884992 11:64117520-64117520
37 FLRT1 NM_014067.4(MACROD1):c.517+34898_517+34918del Deletion Uncertain significance 571356 rs1565240655 11:63883793-63883813 11:64116321-64116341
38 FLRT1 NM_014067.4(MACROD1):c.517+33243C>T SNV Uncertain significance 575806 rs140274429 11:63885468-63885468 11:64117996-64117996
39 FLRT1 NM_014067.4(MACROD1):c.517+34250T>A SNV Uncertain significance 577882 rs1565241569 11:63884461-63884461 11:64116989-64116989
40 FLRT1 NM_014067.4(MACROD1):c.517+34535G>A SNV Uncertain significance 579757 rs756250929 11:63884176-63884176 11:64116704-64116704
41 FLRT1 NM_014067.4(MACROD1):c.517+33906T>G SNV Uncertain significance 640772 rs1590933528 11:63884805-63884805 11:64117333-64117333
42 FLRT1 NM_014067.4(MACROD1):c.517+34305T>C SNV Uncertain significance 643512 rs1590932597 11:63884406-63884406 11:64116934-64116934
43 FLRT1 NM_014067.4(MACROD1):c.517+33198G>A SNV Uncertain significance 645543 rs375487485 11:63885513-63885513 11:64118041-64118041
44 FLRT1 NM_014067.4(MACROD1):c.517+34236G>A SNV Uncertain significance 647420 rs756527574 11:63884475-63884475 11:64117003-64117003
45 FLRT1 NM_014067.4(MACROD1):c.517+33328C>A SNV Uncertain significance 658157 rs1590934834 11:63885383-63885383 11:64117911-64117911
46 FLRT1 NM_014067.4(MACROD1):c.517+34761C>G SNV Uncertain significance 530933 rs777177875 11:63883950-63883950 11:64116478-64116478
47 FLRT1 NM_014067.4(MACROD1):c.517+33591C>T SNV Uncertain significance 530934 rs138289564 11:63885120-63885120 11:64117648-64117648
48 FLRT1 NM_014067.4(MACROD1):c.517+34449C>T SNV Uncertain significance 530935 rs148012979 11:63884262-63884262 11:64116790-64116790
49 FLRT1 NM_014067.4(MACROD1):c.517+33260C>A SNV Uncertain significance 530936 rs143309484 11:63885451-63885451 11:64117979-64117979
50 FLRT1 NM_014067.4(MACROD1):c.517+34743C>T SNV Uncertain significance 530937 rs770193280 11:63883968-63883968 11:64116496-64116496

Expression for Neuritis

Search GEO for disease gene expression data for Neuritis.

Pathways for Neuritis

GO Terms for Neuritis

Cellular components related to Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.8 PMP2 MPZ MBP

Biological processes related to Neuritis according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 TNF MBP IFNG CCL5 CCL4
2 MAPK cascade GO:0000165 9.86 TNF NEFL MBP CCL5
3 chemical synaptic transmission GO:0007268 9.81 PMP22 MPZ MBP CHRNG
4 positive regulation of interleukin-6 production GO:0032755 9.7 TNF MBP IFNG
5 regulation of insulin secretion GO:0050796 9.61 TNF IFNG CCL5
6 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.58 TNF IFNG
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 TNF IFNG CCL5
8 astrocyte activation GO:0048143 9.57 TNF IFNG
9 response to virus GO:0009615 9.56 TNF IFNG CCL5 CCL4
10 positive regulation of signaling receptor activity GO:2000273 9.55 IFNG HFE
11 negative regulation by host of viral transcription GO:0043922 9.54 CCL5 CCL4
12 negative regulation of amyloid-beta clearance GO:1900222 9.49 TNF IFNG
13 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.46 TNF MBP
14 positive regulation of natural killer cell chemotaxis GO:2000503 9.37 CCL5 CCL4
15 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.32 TNF IFNG
16 positive regulation of vitamin D biosynthetic process GO:0060557 9.16 TNF IFNG
17 positive regulation of nitrogen compound metabolic process GO:0051173 8.96 TNF IFNG
18 response to toxic substance GO:0009636 8.92 NEFL MBP CCL5 CCL4

Molecular functions related to Neuritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 TNF IFNG CCL5 CCL4
2 CCR5 chemokine receptor binding GO:0031730 8.96 CCL5 CCL4
3 CCR1 chemokine receptor binding GO:0031726 8.62 CCL5 CCL4

Sources for Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....